// App-Quantinova.ai

: Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials

Researchers

Presenter

  • David Halpin

Principal Investigators

  • Claus F. Vogelmeier

  • Alexander J. Mackay

  • Karen Mezzi

  • Pankaj Goyal

  • Pritam Gupta

  • Konstantinos Kostikas

  • Jadwiga A. Wedzicha

Medical Centers

  • Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • University Medical Center Giessen and Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • Respiratory Clinical Science Section National Heart and Lung Institute, Imperial College London, London, United Kingdom, London, United Kingdom

Locations

  • United Kingdom

  • Germany

  • Switzerland

  • India

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • salmeterol + fluticasone

  • Seebri Breezhaler

  • Fluticasone

  • Fluticasone furoate

  • indacaterol

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved